Comparison of Monotherapy Versus Combination Therapy for Stenotrophomonas maltophilia Pneumonia Including Trimethoprim-Sulfamethoxazole-Containing and -Sparing Regimens

Lake, Patrick; Furuya, E. Yoko; Kubin, Christine J.

doi:10.1093/ofid/ofw172.1577

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, a retrospective cohort study of adult patients with Stenotrophomonas pneumonia compared 61 who were treated with monotherapy compared to 45 who received combination treatment. Patients in the combination subgroup had higher disease severity by Charlson Comorbidity Index and APACHE II score; however, accounting for this on multivariate analysis, there was no discernable difference in mortality, clinical response, microbiological eradication, or resistance development between both treatment groups [48].…”

Section: Combination Treatmentmentioning

confidence: 85%

Antimicrobial Treatment Strategies for Stenotrophomonas maltophilia: A Focus on Novel Therapies

Gibb

Wong

2021

Antibiotics

View full text Add to dashboard Cite

Stenotrophomonas maltophilia is an urgent global threat due to its increasing incidence and intrinsic antibiotic resistance. Antibiotic development has focused on carbapenem-resistant Enterobacteriaceae, Pseudomonas, and Acinetobacter, with approved antibiotics in recent years having limited activity for Stenotrophomonas. Accordingly, novel treatment strategies for Stenotrophomonas are desperately needed. We conducted a systemic literature review and offer recommendations based on current evidence for a treatment strategy of Stenotrophomonas infection.

show abstract

Section: Combination Treatmentmentioning

confidence: 85%

Antimicrobial Treatment Strategies for Stenotrophomonas maltophilia: A Focus on Novel Therapies

Gibb

Wong

2021

Antibiotics

View full text Add to dashboard Cite

show abstract

“…A 2016 retrospective, single-center study published in abstract form sought to compare monotherapy and combination therapy comprised of regimens with and without TMP-SMX [ 87 ]. One hundred six patients were included, 61 who received monotherapy (38 included TMP-SMX) and 45 who received combination therapy (27 included TMP-SMX).…”

Section: Therapeutic Strategiesmentioning

confidence: 99%

Overcoming Stenotrophomonas maltophilia Resistance for a More Rational Therapeutic Approach

Kullar¹,

Wenzler

Alexander

et al. 2022

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Stenotrophomonas maltophilia is an underappreciated source of morbidity and mortality among Gram-negative pathogens. Effective treatment options with acceptable toxicity profiles are limited. Phenotypic susceptibility testing via commercial automated test systems is problematic and no FDA breakpoints are approved for any of the first-line treatment options for S. maltophilia. The lack of modern pharmacokinetic/ pharmacodynamic data for many agents impedes dose optimization and the lack of robust efficacy and safety data limits their clinical utility. Levofloxacin has demonstrated similar efficacy to SMX-TMP, although rapid development of resistance is a concern. Minocycline demonstrates the highest rate of in vitro susceptibility, however, evidence to support its clinical use are scant. Novel agents such as cefiderocol have exhibited promising activity in pre-clinical investigations, though additional outcomes data are needed to determine its place in therapy for S. maltophilia. Combination therapy is often employed despite the dearth of adequate supporting data.

show abstract

Comparison of Monotherapy Versus Combination Therapy for Stenotrophomonas maltophilia Pneumonia Including Trimethoprim-Sulfamethoxazole-Containing and -Sparing Regimens

Cited by 2 publications

References 0 publications

Antimicrobial Treatment Strategies for Stenotrophomonas maltophilia: A Focus on Novel Therapies

Antimicrobial Treatment Strategies for Stenotrophomonas maltophilia: A Focus on Novel Therapies

Overcoming Stenotrophomonas maltophilia Resistance for a More Rational Therapeutic Approach

Contact Info

Product

Resources

About